What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?

Leukemia and Lymphoma

Volumn 49, Issue 9, 2008, Pages 1653-1656

  Gill, Saar ^a   Hicks, Rodney J ^a   Seymour, John F ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BIOPSY TECHNIQUE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE FREE SURVIVAL; ENDOSCOPY; FALSE POSITIVE RESULT; GASTROINTESTINAL DISEASE; GOOD CLINICAL PRACTICE; HEALTH CARE POLICY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NOTE; OVERALL SURVIVAL; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; METHODOLOGY; MINIMAL RESIDUAL DISEASE; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, MANTLE-CELL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY;

EID: 52349115001     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802311433     Document Type: Note

References (27)

1. Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B. Pro, B. et al. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol, 23, pp. 7013-7023.
2. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U. Metzner, B. et al. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol, 23, pp. 1984-1992.
3. Ritchie, D. S., Seymour, J. F., Grigg, A. P., Roberts, A. W., Hoyt, R. Thompson, S. et al. (2007) The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Haematol, 86, pp. 101-105.
4. Vose, J., Loberiza, P., Bierman, G., Bociek, J. and Armitage, J. (2006) Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD/High-dose methotrexate and cytarabine (M-C) (±rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol, 24
5. Gill, S. and Ritchie, D. (2008) Therapeutic options in mantle cell lymphoma. Leuk Lymphoma, 49, pp. 398-409.
6. Juweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y. Wooldridge, J. E. et al. (2005) Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol, 23, pp. 4652-4661.
7. Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T. Jurlander, J. et al. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, pp. 52-59.
8. Ng, A. P., Wirth, A., Seymour, J. F., Lee, M., Hogg, A. Januszewicz, H. et al. (2007) Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma, 48, pp. 596-600.
9. Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L. Horning, S. J. et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol, 25, pp. 579-586.
10. MacManus, M. P., Seymour, J. F. and Hicks, R. J. (2007) Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging, 7, pp. 10-18.
11. Gill, S., Wolf, M., Prince, H. M., Januszewicz, H., Ritchie, D. Hicks, R. J. et al. (2008) 18F-fluorodeoxyglucose positron emission tomography for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymph Myeloma, 8, pp. 159-165.
12. Karam, M., Matthew, W., Shet, N. and Ata, A. (2007) FDG PET study may identify mantle cell lymphoma patients with an unusually favourable prognosis. J Nucl Med, 48
13. Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J. A. Zhuang, H. et al. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 101, pp. 3875-3876.
14. Brepoels, L., Stroobants, S., De Wever, W., Dierickx, D., Vandenberghe, P. Thomas, J. et al. (2008) Positron emission tomography (PET) in mantle cell lymphoma. Leuk Lymphoma, 49, pp. 1693-1701.
15. Leitch, H. A., Gascoyne, R. D., Chhanabhai, M., Voss, N. J., Klasa, R. and Connors, J. M. (2003) Limited-stage mantle-cell lymphoma. Ann Oncol, 14, pp. 1555-1561.
16. McLaughlin, P., Seymour, J. F., Fuller, L. and Cabanillas, F. (1996) Combined modality therapy for stage I-II MALT lymphoma and mantle cell lymphoma. Ann Oncol, 7, pp. 211-213.
17. Romaguera, J. E., Medeiros, L. J., Hagemeister, F. B., Fayad, L. E., Rodriguez, M. A. Pro, B. et al. (2003) Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer, 97, pp. 586-591.
18. Schoder, H., Noy, A., Gonen, M., Weng, L., Green, D. Erdi, Y. E. et al. (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 4643-4651.
19. Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M. Guermazi, A. et al. (2007) Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol, 25, pp. 571-578.
20. Ferrer, A., Bosch, F., Villamor, N., Rozman, M., Graus, F. Gutierrez, G. et al. (2008) Central nervous system involvement in mantle cell lymphoma. Ann Oncol, 19, pp. 135-141.
21. Gill, S., Prince, H. M., Wolf, M. M., Wirth, A., Ryan, G. Carney, D. et al. (2008) Mantle cell lymphoma with central nervous involvement: frequency and clinical features. Ann Oncol, 19, p. iv83.
22. Lapela, M., Leskinen, S., Minn, H. R., Lindholm, P., Klemi, P. J. Soderstrom, K. O. et al. (1995) Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood, 86, pp. 3522-3527.
23. Determann, O., Hoster, E., Ott, G., Wolfram, B. H., Loddenkemper, C. Hansmann, L. M. et al. (2008) Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood, 111, pp. 2385-2387.
24. Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M. Campo, E. et al. (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3, pp. 185-197.
25. Katzenberger, T., Petzoldt, C., Holler, S., Mader, U., Kalla, J. Adam, P. et al. (2006) The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood, 107, p. 3407.
26. Pott, C., Schrader, C., Gesk, S., Harder, L., Tiemann, M. Raff, T. et al. (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood, 107, pp. 2271-2278.
27. Zelenetz, A. D., Persky, D., Rice, R. D., Maragulia, J., Weaver, S. A. Portlock, C. S. et al. (2008) Results of sequential chemotherapy followed by high dose therapy and autologous stem cell rescue for mantle cell lymphoma: Role of rituximab and functional imaging. Ann Oncol, 19, p. iv83.